Xact Kapitalforvaltning AB Purchases 76,301 Shares of Pfizer, Inc. (NYSE:PFE)

Xact Kapitalforvaltning AB increased its stake in Pfizer, Inc. (NYSE:PFE) by 7.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,087,136 shares of the biopharmaceutical company’s stock after buying an additional 76,301 shares during the period. Pfizer makes up 1.1% of Xact Kapitalforvaltning AB’s investment portfolio, making the stock its 11th largest position. Xact Kapitalforvaltning AB’s holdings in Pfizer were worth $37,191,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. D Orazio & Associates Inc. raised its stake in Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares during the last quarter. Naples Global Advisors LLC raised its stake in Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock valued at $840,000 after buying an additional 79 shares during the last quarter. Pure Financial Advisors Inc. raised its stake in Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock valued at $756,000 after buying an additional 84 shares during the last quarter. Alpha Windward LLC raised its stake in Pfizer by 1.1% in the first quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock valued at $287,000 after buying an additional 89 shares during the last quarter. Finally, Peachtree Investment Advisors Inc. raised its stake in Pfizer by 1.3% in the first quarter. Peachtree Investment Advisors Inc. now owns 7,516 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 100 shares during the last quarter. 69.94% of the stock is owned by hedge funds and other institutional investors.

Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.85% during trading on Friday, hitting $32.67. 15,490,145 shares of the stock traded hands. The company has a 50 day moving average of $33.30 and a 200-day moving average of $33.38. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.38. The company has a market cap of $194.30 billion, a PE ratio of 23.90 and a beta of 1.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the business earned $0.64 earnings per share. Pfizer’s revenue was down 1.9% on a year-over-year basis. On average, equities analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s payout ratio is currently 94.12%.

COPYRIGHT VIOLATION WARNING: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/08/19/xact-kapitalforvaltning-ab-has-37-19-million-position-in-pfizer-inc-nysepfe-updated-updated.html.

Several equities research analysts have recently issued reports on PFE shares. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, July 10th. Barclays PLC reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. Sanford C. Bernstein reaffirmed a “buy” rating and set a $37.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. UBS AG reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $35.00 price target (up from $34.00) on shares of Pfizer in a report on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $37.61.

In related news, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit